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Background: Data exploring the potential use of effector molecules produced by cytotoxic T lymphocytes (CTLs) in
the immunodiagnostics of tuberculosis (TB) are scarce. The present study focused a) to gain an insight into the
discriminatory power of CTLs in patients with acute pulmonary or extra-pulmonary TB, or latent tuberculosis
infection (LTBI); and b) to evaluate the influence of various anti-TB therapeutic schemes on the immunological
profiles of residual CTLs.
Methods: Immunological signatures of antigen-specific CTLs were explored in patients with active pulmonary and
extra-pulmonary TB, LTBI and in those treated for TB decades ago by using ELISPOT, intracellular flow cytometry
and extracellular CD107a detection.
Results: No difference was seen between active TB, LTBI or any of those treated for TB in the ELISPOT analysis of
antigen-specific Granzyme B (GrB), Perforin (Prf) and interferon-gamma (IFN-γ) producing lymphocytes, the FACS
analysis of the intracellular expression of IFN-γ, or the surface expression of CD107a degranulation factor of both
CD8+ and CD4+ antigen-specific T cell subsets. The effector memory (TEM) phenotype proved predominant in the
surface marker profiling both in active TB and LTBI. The proportion of the CD107a degranulation factor proved
higher in the central memory (TCM) than in the other cell subsets in all the study groups. Interestingly, functionally
and phenotypically similar CTLs profiles were observed in active TB, LTBI and in all the three groups treated for TB.
Conclusion: The phenotypic and functional profiling of CTLs has a limited potential in the immunodiagnostics of
active TB. Antigen-specific CTLs persist in patients treated for TB decades ago regardless of the efficacy of
implemented and completed anti-TB therapy.
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The interferon-gamma (IFN-γ) releasing antigen-specific
T cells have been extensively exploited in the immunodi-
agnostics of tuberculosis (TB) [1,2]. However, it has be-
come obvious that these IFN-γ release assays (IGRA)
lack diagnostic potential to discriminate active TB from
latent tuberculosis infection (LTBI) or the latter from
immunologic memory [3,4]. Therefore, new biomarkers
or biosignatures of the host response to Mycobacterium
tuberculosis (Mtb) invasion are urgently needed. Ideally,
these biomarkers should provide correlates of both cure* Correspondence: laura.e.savolainen@helsinki.fi
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reproduction in any medium, provided the orand risks for disease progression [5,6]. The polyfunction-
ality of antigen-specific T cells has recently been investi-
gated, but the results appear partially contradictory [7,8].
In active TB, T lymphocytes particularly of the CD4+ T
cell subset have been reported to simultaneously express
multiple effector molecules, e.g. IFN-γ, TNFα and sur-
face degranulation markers CD107a as well as b, but not
IL-2 [7]. Day et al. 2011 have shown that the decline of
the bacterial load during anti-TB treatment is accom-
panied by an increase in the frequency of polyfunctional
IFN-γ+IL-2+TNF-α+ cells. The same has also been re-
ported for CD8+ T cells [8]. Disappointingly, however, in
a recent large prospective evaluation, T cells producing a
single cytokine as well as polyfunctional T cells had only
a limited role in the diagnostics of active TB [9]. Instead,tral Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Savolainen et al. BMC Infectious Diseases 2013, 13:573 Page 2 of 11
http://www.biomedcentral.com/1471-2334/13/573antigen-specific memory CD4+ T cells expressing pro-
grammed death-1 receptor or CD27 were suggested as a
tool for differentiating individuals with LTBI from those
having received adequate anti-TB treatment [10].
Cytotoxic T lymphocytes (CTLs) and natural killer cells
(NK) destroy transformed tumor cells and cells infected
with intracellular pathogens, such as viruses or Mtb
[11,12]. CTLs and NK cells have similar effector functions,
but are triggered by distinct receptors [13]. The elimin-
ation of the target cell is mediated by two major pathways:
ligand-ligand cell death or release of cytolytic molecules,
e.g. Granzyme B (GrB) and Perforin (Prf) from intra-
cytoplasmic granules [11,12]. These cytolytic effector
molecules are preformed within cytoplasmic granules.
Spontaneous leakage of these molecules is prohibited by a
lipid bilayer containing lysosomal-associated membrane
glycoproteins LAMP1 (CD107a), LAMP2 (CD107b), and
LAMP3 [14]. Once a cognate antigen is recognized by T-
cell receptors (TCR), CTLs become activated, which lead
to the polarization of microtubules [12]. This in part facili-
tates the migration of lytic microgranules towards im-
munological synapses formed between the CTL and the
target cell. As the granules reach the cell surface, the
content of the granule with GrB and Prf is released. Sim-
ultaneously, the membrane proteins CD107a and CD107b
become surface-exposed, thus providing a marker of de-
granulation and cytotoxic killing [15]. Until now, the
cytotoxic signatures have not yet been fully exploited in
TB diagnostics because of the lack of reliable and robust
techniques in cytotoxic studies [16]. Although the
methods measuring the functionality of CTLs, e.g. GrB
and Prf ELISPOTs, and extracellular CD107a detection
have been evaluated [15-17], these methods are not
widely used as yet.
We have previously investigated the immunophenoty-
pic profiles of CD4+ T cells in elderly Finnish volunteers
who had completed anti-TB chemotherapy decades ago
[4]. The residual responses to Mtb specific antigens
proved highly variable. The CD4+ T cell subsets carried
an immunophenotype compatible with effector memory
TEM (CD4
+CCR7-CD28-CD45RO+CD45RA-) cells. This
observation left us with a critical question: What makes
the host continue to produce T-cell clones with effectory
functions even after successful chemotherapy? Is it because
of the antigen or bacterial persistence?
This research was conducted to gain an insight into
the discriminatory power of CTLs in TB immunodiag-
nostics. More specifically, we compared the frequencies,
the functional and the phenotypic profiles of CTLs in
patients with acute pulmonary or extra-pulmonary TB
or LTBI, and in healthy BCG vaccinees. The second task
was to investigate whether various anti-TB therapeutic
schemes would influence the immunological profiles of re-
sidual CTLs and to evaluate whether these findings wouldcorrelate with our previously published data on antigen-
specific CD4+ T cells in the same study groups [4].Methods
Patient groups and clinical samples
The study comprised 6 study groups: 21 patients with
active TB and 11 patients with a positive IGRA result,
who had a history of TB exposure, but no symptoms of
active disease, and therefore by definition being assigned
to the group of LTBI. In addition, cryopreserved samples
from patients with TB diagnosed and treated decades
ago were retrieved from the freezer. The samples have
been described in details earlier [4]. In brief, the samples
were grouped as follows: 6 participants were treated with
surgery only, and did not receive any anti-TB treatment
(Surg.); 23 had received partial anti-TB treatment before
the rifampicin (RMP) era (Part.); and 8 were treated with
RMP as a part of modern three-drug therapy (Mod.). In
addition, we tested six samples from healthy Bacillus
Calmette-Guérin (BCG) vaccinees in which LTBI was
excluded by a negative IGRA test. All enrolled persons
have been living in a low TB prevalence country, thus
the re-exposure to Mtb is highly unlikely. The demo-
graphic and clinical data of samples enrolled in this
study are presented in Table 1.
All but one patient in the group with active TB had
positive Mtb culture, or acid fast bacilli at staining, or
both. One patient was diagnosed on the basis of clinical
and radiological findings and a good response to anti-TB
treatment. The samples were taken no later than 2 weeks
after the diagnosis. From the group with active TB, 18
had pulmonary presentation, 2 had TB of mesentery
lymphatic nodes and 1 had TB spondylitis.Recombinant proteins
Recombinant Mtb proteins were expressed in and purified
from Escherichia coli M15. Genes encoding culture filtrate
protein-10 (cfp-10) and early secretory antigen target-6
(esat-6) were PCR- amplified using purified chromosomal
Mtb DNA as the template and primers designed to amp-
lify the coding sequence. The genes were cloned into the
pQE30 vector using the QIAexpress System (QIAGEN,
GmbH, Germany). The recombinant proteins containing
an N-terminal histidine tag (rCFP-10 and rESAT-6) were
overexpressed and affinity purified, as previously described
[18]. The purity and the apparent molecular weight of
the expressed proteins were confirmed by SDS-PAGE
gel electrophoresis and Western blotting with anti-His
antibodies (Clontech Laboratories, CA, USA). Concen-
tration of endotoxin in the protein samples was deter-
mined by Limulus amebocyte lysate assay (GenScript
inc., Piscataway, NY, USA), and was found to be below
0.1 EU/ml.
Table 1 Demographic and clinical data
Patient groups n Finns n (%) Age range Female sex
n (%)
AFB pos.
n (%)
Culture pos.
n (%)
Other method n (%)
Active-TB (TB)
Pulmonary 18 14 (78) 27 - 81 6 (33) 14 (78) 17 (94) Clinical presentation and
response to treatment: 1 (6)
Other organs 3 2 (67) 33 - 62 1 (33) 0 (0) 3 (100)
LTBI 11 10 (91) 43 - 80 4 (36) n/d n/d IGRA pos: 11 (100)
Treated patients - no chemotherapy
(Surg.)
6 6 (100) 53 - 83 2 (33) n/d n/d n/d
Treated patients - partial treatment
(Part.)
23 23 (100) 71 - 90 18 (78) n/d n/d n/d
Treated patients - modern three-drug
treatment (Mod.)
8 7 (86) 45 - 84 7 (86) n/d n/d n/d
Healthy BCG-vaccinees (BCG) 6 6 (100) 33 - 44 6 (100) n/d n/d IGRA neg.: 6 (100)
n/d = not defined.
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Ficol density gradient (Amersham Biosciences AB, Uppsala,
Sweden) was used to isolate peripheral blood mononuclear
cells (PBMCs). To avoid the stimulation of cells with
fetal calf serum (FCS), the cells were preserved in
CryoABC Kit (CTL-Europe, GmpH, Bonn, Germany) in
liquid nitrogen until use [19]. The GrB, Prf and IFN-γ
ELISPOTs were performed with the commercial kits ac-
cording to manufacturer’s instructions (Mabtech, Nacka
Strand, Sweden). In GrB and Prf assays the cells were
stimulated immediately after thawing for 22 hrs with
purified protein derivative (PPD) (Statens Serum Insti-
tut (SSI), Copenhagen, Denmark), rCFP-10 and rESAT-
6 (10 μg/ml, each). In the IFN-γ assay, the stimulation was
carried out with PPD (10 μg/ml), and CFP-10 and ESAT-6
peptide pools, 50 μl/100 μl cell suspension (Oxford
Immunotec, Oxford, UK). In all assays 2×105 PBMCs
were plated per well, and phytohemagglutinin (PHA)
(Oxford Immunotec) stimulation was performed to as-
sure the viability of cells. The spots were counted and
their sizes were analyzed with the ELISPOT-reader
(BIO-SYS-GmbH, Karben, Gemany). Media controls
were subtracted to calculate the net values. In a few pa-
tients, the number of cells isolated proved too low to
allow all experiments to be carried out.
Flow cytometric staining and analysis
PBMCs purified with density gradient and stored in
liquid nitrogen were thawed, and 5×105 cells were incu-
bated with PPD (10 μg/ml), or with media alone, over-
night at 37°C with 5% CO2 in RPMI-10% FCS (HaartBio,
Helsinki, Finland; Sigma-Aldrich, Saint Louis, USA).
FITC-conjugated CD107a antibody (5 μl/1×106 cells,
eBioscience, Inc., San Diego, CA, USA) was added to the
cells before stimulation. After 2 hours incubation, Brefel-
din A (eBioscience) was added. Then, after an overnight
incubation, the cells were washed with PBS-0,1% FCS,and surface-stained in the same buffer with anti-CD8-
Horizon-V450 (5 μl/1×106 cells) and anti-CD4-Alexa
Fluor® 700 (0.4 μg/1×106 cells) (Becton Dickinson (BD),
Franklin Lakes, NJ, USA) 30 min on ice. After treatment
with a fixation buffer for 20 min in RT (eBiosciences),
the cells were washed two times with permeabilzation
buffer (eBiosciences). The cells were stained for 20 min
in RT with anti-IFN-γ-PE-Cy7 (0.2 μg/1×106 cells)
(eBioscience) in a permeabilization buffer. After wash-
ing with the same buffer the cells were resuspended
with PBS-0,1% FCS, and analyzed. The percentages of
CD107a and IFN-γ positive cells were calculated. CD4+
and CD8+ T cells were analyzed separately and the back-
ground (unstimulated cells) was subtracted.
For phenotypic characterization, the PBMCs were stim-
ulated and stained for detection of CD107a as described
above. After overnight incubation, the cells were washed
with PBS-0,1% FCS and surface-stained with anti-CD8-
Horizon-V450 (5 μl/1×106 cells) (BD), anti-CD45RA-PE-
Cy7 (5 μl/1×106 cells) (eBioscience), and anti-CCR7-PE
(5 μl/1×106 cells) (eBioscience). The CD8+ T cells with dif-
ferent combinations of CD45RA and CCR7 markers were
gated, and CD107a positive cells were analyzed from all of
the gates, and the background was subtracted.
Analysis of flow cytometric results
The samples were analyzed by FACSAria (BD) flow cyt-
ometer. To optimize the compensation settings, the BD™
CompBeads Compensation Particles were used (BD).
The lymphocytes were gated according to forward and
side scatter, and at least 100,000 events were acquired.
To analyze the plots, the FACSDiva Version 6.1.3 soft-
ware (BD) was used.
Statistics
The data analysis was carried out with GraphPad Prism
version 4.0 (GraphPad Software, Inc. San Diego, CA.).
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Wallis test, with Dunn’s multiple comparison, or Mann-
Whitney U-test. The correlation analysis was performed
with the non-parametric Spearman’s rank correlation test.
The p value < 0.05 was considered significant.Ethics statement
The study was approved by the Southwest Finland district
Ethical Committee (DroNo 47/180/2009), Helsinki and
Uusimaa Hospital district Ethical Committee of Medicine
(DroNo 356/E5/07), Helsinki and Uusimaa Hospital dis-
trict (149/2010) and University hospital of Kuopio (105/
2010). Those patients who were in a regular ward gave
written consents. The patients who were in the isolation
rooms gave their verbal consents by phone. The day and
time of the phone call were documented. All patients re-
ceived written and verbal information. This was a routine
ethical procedure accepted in our hospital.Figure 1 Frequencies of cells producing effector molecules measured
stimulated with PPD (A,C,E), rCFP-10 (B,D), and the CFP-10 peptide pool (F
lines represent the cut-offs for the positive IFN-γ results, and lower dashed
LTBI, n = 9 (rCFP-Prf n = 7), Surg., n = 6 (rCFP-Prf n = 4), Part., 23 (rCFP-Prf n =
IFN-γ n = 5), (rCFP-perforin n = 3), BCG+, n = 6 (PPD-GrB, rCFP-GrB, PPD-Prf nResults
Enumeration of GrB, Prf and IFN-γ-producing T cells
To determine the cytolytic potential of the CTLs, the fre-
quencies of antigen-specific GrB, Prf and IFN-γ producing
lymphocytes were analyzed with ELISPOT (Figure 1).
Inter-individual variations proved high, yet no statistically
significant differences were observed between the TB and
LTBI groups. In the majority of the study groups, the me-
dian frequency for GrB-producing cells was higher than
for those producing Prf. Stimulation with rESAT-6 and
rCFP-10 induced similar output responses, yet the back-
ground was slightly higher with rESAT-6 (data not shown).
Noteworthy, the background was high for both markers
probably due to handling of cells which resulted in a spon-
taneous release of effector molecules. Although the groups
were small, the frequencies of IFN-γ and GrB producing
CTLs proved to differ significantly (p < 0.05) between the
subjects receiving the 3-drug therapy (Mod.) and those
treated with surgery (Surg.) (Figure 2).by ELISPOT. GrB (A-B), Prf (C-D) and IFN-γ- producing cells (E-F) were
). Horizontal bars indicate the medians of the responses. Upper dashed
lines cut-offs for the negative results (E-F). TB, n = 17 (rCFP-Prf n = 13),
21), Mod., n = 7 (rCFP-GrB n = 6), (CFP-peptides-IFN-γ, PPD-Prf, PPD-
= 4, rCFP-Prf n = 3).
Figure 2 Comparison of the ELISPOT immune responses in treated patients. Frequencies of IFN-γ and GrB producing cells when stimulated
with PPD (A,C), CFP-10 peptide pool (B) or rCFP-10 (D). The median values are shown with horizontal bars. Surg., n = 6, Part., n = 23, Mod., n = 7
(rCFP-GrB n = 6; PPD-IFN-γ, CFP-peptides-IFN-γ n = 5).
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The intracellular expression of IFN-γ, and surface expres-
sion of CD107a were analyzed by FACS. Gating strategy
and representative dot plots are shown in Figure 3A. No
statistically significant differences between the study
groups were observed. When results from all the subjects
were pooled, the frequency of antigen-specific CD107a de-
granulation factor proved significantly higher (p < 0.01) in
the CD8+ (Figure 3B) than in the CD4+ T cell subset
(Figure 3C), whereas reciprocally, a higher production of
IFN-γ was found in the CD4+ (p < 0.0001) than the CD8+
T cell subset (Figure 3D and E). The CD107a and IFN-γ
double positive cells yielded very low frequencies in both
cell phenotypes (data not shown). In one person treated
with modern therapy, the frequency of the CD4+ IFN-γ-
producing T cells reached 6.74% (data not shown). Taken
together, functionally active CTLs were detected in all the
study groups.
Correlation between expressions and production of
different markers of cytotoxicity
The correlation between the CD107a expression (FACS)
and the production of GrB and Prf (ELISPOT) was stud-
ied with the Spearman’s rank correlation test. A positive
correlation between GrB and Prf was found only for the
LTBI patient group (r = 0.78, p < 0.05). A significant posi-
tive correlation (r = 0.41, p < 0.05) was detected also
between CD8+CD107a+ expression and GrB productionwhen all the patient samples were subjected to the ana-
lysis. Poor correlation between the results from different
methods suggests either that the expression of cytotox-
icity signature markers occurs independently, or that the
markers are short-lived.Phenotypic analysis of CD8+CD107a+ T cells
CTLs from three samples of each group were analyzed
on the basis of the following classification: CD45RA+
CCR7+ naive (TN), CD45RA
–CCR7+ central memory
(TCM), CD45RA
–CCR7– effector memory (TEM), and
CD45RA+CCR7– terminally-differentiated effector mem-
ory (TEMRA) cells [20]. Representative dot plots are shown
in Figure 4A. Figure 4B shows that the TEM phenotype
was predominant in the TB, LTBI, Surg. and Part. groups
but not in the Mod. and the BCG groups (Figure 4B). As
expected, in the BCG group the TN was predominant, yet
the other phenotypes with effector functions were de-
tected as well. The degranulation marker CD107a proved
more prominent in the TCM than in the other phenotypic
subpopulations. Together these results show that the
phenotypic profiles of the cells in the circulation are
similar in active TB, LTBI and in treated patients. The
only group with a predominance of TEMRA cells was the
one with three-drug modern therapy, yet this difference
needs to be confirmed in future experiments with larger
study groups.
Figure 3 Flow cytometric analysis for CD107a degranulation marker and IFN-γ production in CD8+ and CD4+ T cell subsets. The
frequencies of CD107a and IFN-γ expressing cells were analyzed from CD8+ and CD4+ T cell subsets (A). The cells were stimulated with PPD and
the percentages of CD8+ and CD4+ T cells expressing CD107a (B,C) and IFN-γ (D,E) are calculated after the subtraction of the corresponding re-
sults from non-stimulated cells. The horizontal bars represent the medians of the responses. TB, n = 13, LTBI, n = 5, Surg., n = 5, Part., n = 5, Mod.,
n = 5 (CD4+IFN-γ+ n = 4), BCG+, n = 5.
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Significant negative correlation with age was found in
CD4+IFN-γ+ T cells: r = −0.424, p < 0.01. Analysis of GrB
and IFN-γ ELISPOTs resulted: r = −0.237, p = 0.053;
r = −0.231, p = 0.060, respectively (Spearman’s rank correl-
ation test). The gender had no effect on the results of
immunological signatures when tested with the Mann-
Whitney U-test.
Discussion
We have earlier reported that effector memory CD4+ T
cells persist in TB patients treated decades ago with
different schemes, including bactericidal RMP [4]. Here,
we present novel data demonstrating that functionally
active antigen-specific CTLs expressing various effectormolecules also persist in patients treated for TB. Indeed,
the surface degranulation marker, i.e. CD107a, the cyto-
toxic signatures of CTLs, and their frequencies did not
differ significantly between groups of treated patients
and active TB or LTBI. Although the groups were small,
GrB and IFN-γ-producing CTLs appeared to be more
frequent in the Mod. than the Surg. group. Disappoint-
ingly, however, the functional and phenotypic profiling
of CTLs performed with various methods and using
different activation markers or combinations resulted in
no discrimination between the active TB and the LTBI
groups or any of the groups treated for TB.
Relatively small cohorts of patients with active TB and
LTBI which were not matched for gender or age is a
limitation of our study. Another limitation of ours as of
Figure 4 (See legend on next page.)
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Figure 4 Phenotypic assessment of the CD8+CD107a+ T cell subsets using the FACS analysis. The quantities of CD107a expressing cells
were analyzed from the CD8+ T cell subset with different combinations of CD45RA and CCR7 surface markers after the PPD stimulation (A). The
phenotypic distribution of TN, TCM, TEM and TEMRA cell subsets within the CD8
+CD107a+ T cell pool was assessed in different study groups. The
TEM phenotype predominated in the TB., LTBI., Surg. and Part. groups whereas in the BCG vaccinees’ group the predominat subset was TN (B).
The percentages of positivity for CD107a, the degranulation factor, within each phenotypic subpopulation in different study groups was assessed.
This marker of cell activation was most prevalent within the TCM cell subpopulation throughout all the study cohort (C). The responses from non-
stimulated cells were subtracted from the PPD responses. Three samples from each group were tested, and the means with corresponding ranges
are shown for TN, TCM, TEM and TEMRA cell subsets.
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TB infection into categories compatible with recently ac-
cepted notion that TB infection is in fact a continuum of
infection severity starting from real latency through sub-
clinical infection and ending with active disease [21].
From the point of view of the today’s knowledge the di-
chotomous division of infection into active TB and LTBI
seems too simplistic.
The majority of antigen-specific CD8+ T cells were
found to present with the TEM and TEMRA phenotypes,
the finding consistent with previous studies [20,22]. TCM
and TN cells were also found in the periphery of all the
subjects. Some other studies have demonstrated antigen-
specific naïve T cells (up to 90%) also in BCG vaccinated
children and in TB patients [23,24], and TCM cells (15%-
25%) in TB patients at diagnosis and after four months
of treatment [22]. The TCM cell population also appeared
to have the highest proportion of CD107a degranulation
factor. This may indicate that this cell subset, while
representing a minor population in the peripheral circu-
lation could have an important role in inducing rapid
immunologic protection against new challenges by the
recently encountered pathogen.
It proved difficult to underpin a sustained correlation
between the production of the cytolytic molecules, IFN-
γ, and the expression of the CD107a. The expression, re-
lease and degranulation of these effector molecules as
well as their presence in the granules appears highly
dynamic and not interconnected [12,25,26], making this
kind of an approach irreproducible. Therefore this ap-
proach does not seem clinically applicable to definitive
differentiation of the various stages of TB infection.
However, it may be intriguing in the future to reproduce
cytotoxicity studies with other antigens, notably encoded
by dormancy regulon (dosR) [27].
Although the function of CTLs has been studied both
in human and murine TB models [28-33], their role in
both infection defense and diagnostic potential remains
unsettled. Compared to healthy TB contacts, patients
with active TB presented with lower effector functions,
e.g. GrB and Prf production [28,32]. When categorizing
the patients with active TB into “mild” and “advanced”
forms of infection (American Tuberculosis Society cri-
teria) [30], the lytic activity of CTLs was found to belower in the “advanced” than in the “mild” active TB or
healthy PPD+ persons [30], suggesting exhaustion of
CTLs. Exhaustion of T cells has been described also in
many chronic viral infections, such as HIV, hepatitis C
or hepatitis B virus [34,35]. It has been assumed that in
chronic human viral infections, e.g. with cytomegalo-
virus (CMV) or herpes simplex virus 1 (HSV-1), the per-
sistence of antigen will maintain the expansion of the
functional memory T cell pool, the so-called inflationary
T cells [36]. In a murine CMV infection model, inflated
T cells in the spleen or blood were found functional and
short-lived [37]. They can be renewed by cells primed
during acute infection [37]. Here we also show that
functional CD8+ T cells are present in the periphery in
subjects adequately treated for TB decades ago. It thus
appears that, like CMV, TB is a chronic infection exert-
ing continued antigenic burden of T cells, finally leading
to the expansion of antigen-specific T cell clones.
In CD8+ T cells subset, the cytotoxic potential and the
expression of cytolytic molecules have been attributed
especially to the CD45RA+CCR7– TEMRA phenotype,
and to a lesser extent, to CD45RA–CCR7– TEM pheno-
type [38]. By contrast, the CD45RA–CCR7+ TCM and
CD45RA+CCR7+ TN CD8
+ T cells have been reported
to express GrB after a 4-day priming [38]. In our study,
functional TEMRA and TEM cells were found already
after an overnight stimulation. In humans, GrB and Prf
production and CD107a expression have been reported
to correlate with cytotoxicity, in a study combining ELI-
SPOT and CD107a FACS analysis with the results of Cr
release assay [15-17]. By contrast, in a murine TB model,
the CD107a expression has been correlated with cytotox-
icity in primary, but not in secondary infection [39]. In an-
other murine TB model [40], in secondary infection the
cells contained Prf, but were not found cytotoxic. It has
been speculated that T cells can degranulate and express
CD107a even in the absence of the effector molecules
[41]. In these studies [39-41], however, the reduction of
CTL quality was caused by a lack of cytolytic molecule
excretion.
The central dogma of TB pathogenesis has been that
Mtb, an intracellular pathogen, infects and replicates, or
sits quiescent in different cell lineages [6,42]. If the innate
host immunity is inadequate to eradicate the invaded
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munity is a cell-mediated response, particularly of the
Th1-type [6]. In response to the invasion, the host will
“wall-off” the site of the infection by aggregating immune
cells in a compact granuloma, a hallmark of TB. The
granuloma is formed by various cell types among which
CTLs constitute the majority. Interestingly, new discover-
ies obtained through imaging studies have enabled revisit-
ing the role of granuloma in the containment of infection
[43]. It is known that CTLs may be engaged to the target
cells through the FAS ligand exertion, but this interaction
may not necessarily eliminate the intracellular pathogen
[43]. Thus, instead of killing, CTLs, like other immune
cells, may aid bacterial proliferation.
Here we show that antigen-specific CTLs persist in TB
patients treated with a three-drug regimen including
bactericidal RMP. Where do these cells originate from,
and how does the host benefit from maintaining these
cell pools? One plausible but non-canonic explanation
would be that during the over 9000-year evolutionary
co-existence of Mtb with the host [44], a symbiotic rela-
tionship has evolved. The persistence of latency at some
level would have up-regulated the basal activation state
of the innate immunity against subsequent infections.
The latency would have led to systemic activation of
macrophages, and thus, through the polarized cytokine
environment with a predominance of IFN-γ production,
shifted the balance to the Th1 arm of the acquired im-
munity. In other words, the latency might have created a
constant level of alertness against new invaders.
“The hygiene hypothesis” has been put forward to
explain the growing rate of allergic conditions in the
Western population [45,46]. This theory explains why the
immune system will not be primed in infants living in en-
vironments sheltered from constant and excessive contact
with bacteria, and later the immune response will be
shifted towards the Th2 arm. The factors responsible for
this priming are not clear: the role of bacteria belonging
to the Enterobactriacae family has been discussed, while
the possibility of the intracellular Mtb being beneficial has
never been considered. Our observation that CTL sub-
types persist after treated infection suggests that treatment
may never lead to sterile immunity, but instead, once in-
fected, a person would stay infected ever after. The fact
that the LTBI is estimated to be present in almost 1/3 of
the world’s population [47] might explain why, over the
course of co-evolution, the LTBI might have turned even
beneficial to the host. Of course, any potential benefit of
latent infection for the survival of homo sapiens species
requires that the disease mostly remains latent: indeed.
An overt clinical TB will only develop in approximately
5% of those infected, while the rest of the cases remain
latent throughout the individual’s lifetime [1]. We are
fully aware that proposed hypothesis contradicts theestablished attitude towards LTBI as a harmful reservoir
of TB. However, new evidence of latent infections pro-
tecting against other, more detrimental ones has been
obtained with a murine model. It has been established
that mice latently infected with intracellular Epstein-
Barr virus (EBV) or CMV confer symbiotic protection
against bacterial infection [48]. The protection is not
considered complete, thus the hypothesis proposed does
not contradict the fact that a re-infection can occur
after a treated episode of TB.
Conclusions
Functional CTLs persist in patients treated for TB even
decades ago. On the basis on this finding it seems that
the functional and phenotypical profiling of CTLs has a
limited role as an adjunct immunodiagnostic tool for TB
diagnostics. Further studies are warranted to learn about
the clinical significance of persisting antigen-specific
CTLs.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
LS: Designed the study, performed the analyses, interpreted the data and
collected clinical samples. PK: Collected clinical samples, interviewed the
patients and analyzed demographic and clinical data. AK: Collected clinical
samples and applied for the ethical clearances. HV, LP, RT: Collected clinical
samples. BWW: Supervised the production of recombinant proteins. TT:
Designed the study, applied for the ethical clearances, interpreted the data
and with LS wrote the first draft. All authors contributed to the manuscript
preparation, read, approved and accepted the final version.
Acknowledgements
This work was supported by the Tuberculosis Association of the University of
Tampere, the Nummela Sanatorium Association, the Foundation of the
Finnish Anti-Tuberculosis Association, the Research foundation of the pul-
monary diseases, the Väinö and Laina Kivi Foundation, the University of
Helsinki and the Academy of Finland. We want to thank HUSLAB (Helsinki),
the Department of Virology and Immunology for placing the ELISPOT reader
at our disposal. We thank the clinicians from the Peijas Hospital (Vantaa) and
the Department of Mycobacteriology, HUSLAB, for help in recruiting TB
patients.
Author details
1Department of Bacteriology and Immunology, Haartman Institute, University
of Helsinki, PL 21, Helsinki 00014, Finland. 2Division of Infectious Diseases,
Department of Medicine, Helsinki University Central Hospital, Helsinki,
Finland. 3Institute of Clinical Medicine, Department of Medicine, University of
Helsinki, Helsinki, Finland. 4Division of Rheumatology, Department of
Medicine, Helsinki University Central Hospital, Helsinki, Finland.
5Länsi-Uusimaa Hospital, Tammisaari, Finland. 6Division of General
Microbiology, Department of Biosciences, University of Helsinki, Helsinki,
Finland. 7Eastern Finland Laboratory Centre Joint Authority Enterprise,
Mikkeli, Finland.
Received: 16 July 2013 Accepted: 4 December 2013
Published: 5 December 2013
References
1. Centre for Disease Control and Prevention: Updated guidelines for using
interferon-gamma release assays to detect Mycobacterium tuberculosis infec-
tion. United States: CDC; 2010. Available at: http://www.cdc.gov/mmwr/pdf/
rr/rr5905.pdf.
Savolainen et al. BMC Infectious Diseases 2013, 13:573 Page 10 of 11
http://www.biomedcentral.com/1471-2334/13/5732. European Centre for Disease Prevention and Control: Use of interferon-
gamma release assays in support of TB diagnosis. Stockholm: EDCD; 2011.
Available at: http://ecdc.europa.eu/en/publications/Publications/
1103_GUI_IGRA.pdf.
3. Menzies D, Pai M, Comstock G: Meta-analysis: new tests for the diagnosis
of latent tuberculosis infection: areas of uncertainty and
recommendations for research. Ann Intern Med 2007, 146:340–354.
4. Tapaninen P, Korhonen A, Pusa L, Seppälä I, Tuuminen T: Effector memory
T-cells dominate immune responses in tuberculosis treatment: antigen
or bacteria persistence? Int J Tuberc Lung Dis 2010, 14:347–355.
5. McNerney R, Maeurer M, Abubakar I, Marais B, McHugh TD, Ford N, Weyer K,
Lawn S, Mwaba P, Zijenah L, Hoelscher M, Cox H, Swaminathan S, Kim PS,
Schito M, Harari A, Bates M, Schwank S, O’Grady J, Pletschette M, Ditui L,
Atun R, Zumla A: Tuberculosis diagnostics and biomarkers: needs,
challenges, recent advances opportunities. J Infect Dis 2012, 205:147–158.
6. Walzl G, Ronacher K, Hanekom W, Scriba TJ, Zumla A: Immunological
biomarkers of tuberculosis. Nat Rev Immunol 2011, 11:343–354.
7. Young JM, Adetifa IMO, Ota MOC, Sutherland JS: Expanded polyfunctional
T cell responses to Mycobacterial antigens in TB disease and contraction
post-treatment. PLoS ONE 2010, 5:e11237.
8. Day CL, Abrahams DA, Lerumo L, Janse van Rensburg E, Stone L, O’rie T,
Pienaar B, de Kock M, Kaplan G, Mahomed H, Dheda K, Hanekom WA:
Functional capacity of Mycobacterium tuberculosis-specific T cell re-
sponses in humans is associated with mycobacterial load. J Immunol
2011, 187:2222–2232.
9. Nemeth J, Winkler HM, Boeck L, Adegnika AA, Clement E, Mve TM,
Kremsner PG, Winkler S: Specific cytokine patterns of pulmonary
tuberculosis in Central Africa. Clin Immunol 2011, 138:50–59.
10. Adekambi T, Ibegbu CC, Kalokhe AS, Yu T, Ray SM, Rengarajan J: Distinct
effector memory CD4+ T cell signatures in latent Mycobacterium
tuberculosis infection, BCG vaccination and clinically resolved
tuberculosis. PLoS ONE 2012, 7:e36046.
11. Lord SJ, Rajotte RV, Korbutt GS, Bleackley RC: Granzyme B: a natural born
killer. Immunol Rev 2003, 193:31–38.
12. Barry M, Bleackley RC: Cytotoxic T lymphocytes: all roads lead to death.
Nat Rev Immunol 2002, 2:401–409.
13. Lieberman J: The abcs of granule-mediated cytotoxicity: new weapons in
the arsenal. Nat Rev Immunol 2003, 3:361–370.
14. Peters PJ, Borst J, Oorschot V, Fukuda M, Krähenbühl O, Tschopp J, Slot JW,
Geuze HJ: Cytotoxic T lymphocyte granules are secretory lysosomes,
containing both perforin and granzymes. Clin Exp Immunol 1991,
173:1099–1109.
15. Betts MR, Brenchley JM, Price DA, De Rosa SC, Douek DC, Roederer M, Koup
RA: Sensitive and viable identification of antigen-specific CD8+ T cells by
a flow cytometric assay for degranulation. J Immunol Methods 2003,
281:65–78.
16. Rininsland FH, Helms T, Asaad RJ, Boehm BO, Tary-Lehmann M: Granzyme
B ELISPOT assay for ex vivo measurements of T cell immunity. J Immunol
Methods 2000, 240:143–155.
17. Zuber B, Levitsky V, Jonsson G, Paulie S, Samarina A, Grundstrom S, Metkar
S, Norell H, Callender GG, Froelich C, Ahlborg N: Detection of human
perforin by ELISpot and ELISA: ex vivo identification of virus-specific
cells. J Immunol Methods 2005, 302:13–25.
18. Franken LMC, Hiemstra HS, van Meijgaarden KE, Subronto Y, den Hartigh J,
Ottenhoff THM, Drijfhout W: Purification of His-tagged proteins by immo-
bilized chelate affinity chromatography: the benefits from the use of or-
ganic solvent. Protein Exper Purif 2000, 18:95–99.
19. Tuuminen T, Sorva S, Liippo K, Vasankari T, Soini H, Eriksen-Neuman B,
Miettinen A, Seppälä IJ: Feasibility of commercial interferon-gamma-
based methods for the diagnosis of latent Mycobacterium tuberculosis
infection in Finland, a country of low incidence and high bacille
Calmette-Guerin vaccination coverage. Clin Microbiol Infect 2007,
13:836–838.
20. Caccamo N, Guggino G, Meraviglia S, Gelsomino G, Di Carlo P, Titone L,
Bocchino M, Galati D, Matarese A, Nouta J, Klein MR, Salerno A, Sanduzzi A,
Dieli F, Ottenhoff TH: Analysis of Mycobacterium tuberculosis-specific
CD8 T-cells in patients with active tuberculosis and in individuals with la-
tent infection. PLoS ONE 2009, 4:e5528.
21. Barry CE 3rd, Boshoff HI, Dartois V, Dick T, Ehrt S, Flynn J, Schnappinger D,
Wilkinson RJ, Young D: The spectrum of latent tuberculosis: rethinking
the biology and intervention strategies. Nat Rev Microbiol 2009, 7:845–855.22. Caccamo N, Meraviglia S, La Mendola C, Guggino G, Dieli F, Salerno A:
Phenotypical and functional analysis of memory and effector human
CD8 T cells specific for mycobacterial antigens. J Immunol 2006,
177:1780–1785.
23. Soares AP, Scriba TJ, Joseph S, Harbacheuski R, Murray RA, Gelderbloem SJ,
Hawkridge A, Hussey GD, Maecker H, Kaplan G, Hanekom WA: Bacillus
Calmette-Guérin vaccination of human newborns induces T cells with
complex cytokine and phenotype profiles. J Immunol 2008, 5:3569–3577.
24. Axelsson-Robertson R, Loxton AG, Walzl G, Ehlers MM, Kock MM, Zumla A,
Maeurer M: A broad profile of co-dominant epitopes shapes the periph-
eral Mycobacterium tuberculosis specific CD8+ T-cell immune response
in South African patients with active tuberculosis. PLoS ONE 2013,
8:e58309.
25. Rock MT, Yoder SM, Wright PF, Talbot TR, Edwards KM, Crowe JE Jr:
Differential regulation of granzyme and perforin in effector and memory
T cells following smallpox immunization. J Immunol 2005, 174:3757–3764.
26. Takata H, Takiguchi M: Three memory subsets of human CD8+ T cells
differently expressing three cytolytic effector molecules. J Immunol 2006,
177:4330–4340.
27. Goletti D, Butera O, Vanini V, Lauria FN, Lange C, Franken KL, Angeletti C,
Ottenhoff TH, Girardi E: Response to Rv2628 latency antigen associates with
cured tuberculosis and remote infection. Eur Respir J 2010, 36:135–142.
28. Kumar MM, Raja A: Cytotoxicity responses to selected ESAT-6 and CFP-10
peptides in tuberculosis. Cell Immunol 2010, 265:146–155.
29. Kamath A, Woodworth JSM, Behar SM: Antigen-specific CD8+ T cells and
the development of central memory during Mycobacterium tuberculosis
infection. J Immunol 2006, 177:6361–6369.
30. De la Barrera SS, Finiasz M, Frias A, Aleman M, Barrionuevo P, Fink S, Franco
MC: Specific lytic activity against mycobacterial antigens is inversely
correlated with the severity of tuberculosis. Clin Exp Immunol 2003,
132:450–461.
31. Canaday DH, Wilkinson RJ, Li Q, Harding CV, Silver RF, Boom WH: CD4(+)
and CD8(+) T cells kill intracellular Mycobacterium tuberculosis by a
perforin and Fas/Fas ligand-independent mechanism. J Immunol 2001,
167:2734–2742.
32. Smith SM, Klein MR, Malin AS, Sillah J, Huygen K, Andersen P, McAdam KP,
Dockrell HM: Human CD8(+) T cells specific for Mycobacterium
tuberculosis secreted antigens in tuberculosis patients and healthy BCG-
vaccinated controls in The Gambia. Infect Immun 2000, 68:7144–7148.
33. Pathan AA, Wilkinson KA, Wilkinson RJ, Latif M, McShane H, Pasvol G, Hill AV,
Lalvani A: High frequencies of circulating IFN-γ-secreting CD8 cytotoxic T
cells specific for a novel MHC class I-restricted Mycobacterium tubercu-
losis epitope in M. tuberculosis-infected subjects. Eur J Immunol 2000,
30:2713–2721.
34. Wherry EJ: T cell exhaustion. Nat Immunol 2011, 12:492–499.
35. Virgin HW, Wherry EJ, Ahmed R: Redefining chronic viral infection.
Cell 2009, 138:30–50.
36. O’Hara GA, Welten SP, Klenerman P, Arens R: Memory T cell inflation:
understanding cause and effect. Trends Immunol 2012, 33:84–90.
37. Snyder CM, Cho KS, Bonnett EL, van Dommelen S, Shellam GR, Hill AB:
Memory inflation during chronic viral infection is maintained by
continuous production of short-lived, functional T cells. Immunity 2008,
29:650–659.
38. Meng Y, Harlin H, O’Keefe JP, Gajewski TF: Induction of cytotoxic granules
in human memory CD8+ T cell subsets requires cell cycle progression.
J Immunol 2006, 177:1981–1987.
39. Einarsdottir T, Lockhart E, Flynn JL: Cytotoxicity and secretion of gamma
interferon are carried out by distinct CD8 T cells during Mycobacterium
tuberculosis infection. Infect Immun 2009, 77:4621–4630.
40. Lazarevic V, Nolt D, Flynn JL: Long-term control of Mycobacterium
tuberculosis infection is mediated by dynamic immune responses.
J Immunol 2005, 175:1107–1117.
41. Wolint P, Betts MR, Koup RA, Oxenius A: Immediate cytotoxicity but not
degranulation distinguishes effector and memory subsets of CD8+ T
cells. J Exp Med 2004, 199:925–936.
42. Lawn SD, Zumla AI: Tuberculosis. Lancet 2011, 378:57–72.
43. Ramakrihnan L: Revisiting the role of the granuloma in tuberculosis.
Nat Rev Immunol 2012, 12:352–356.
44. Hershkovitz I, Donoghue HD, Minnikin DE, Besra GS, Lee OY, Gernaey AM,
Galili E, Eshden V, Greenblatt CL, Lemma E, Bar-Gal GK, Spigelman M: Detec-
tion and molecular characterization of 9,000-year-old Mycobacterium
Savolainen et al. BMC Infectious Diseases 2013, 13:573 Page 11 of 11
http://www.biomedcentral.com/1471-2334/13/573tuberculosis from a Neolithic settlement in the Eastern Mediterranean.
PLoS ONE 2008, 10:e3426.
45. Okada H, Kuhn C, Feillet H, Bach J-F: The ‘hygiene hypothesis’ for auto-
immune and allergic diseases: an update. Clin Exp Immunol 2010, 160:1–9.
46. Wold AE: The hygiene hypothesis revised: is the rising frequency of
allergy due to changes in the intestinal flora? Allergy 1998, 53:20–25.
47. WHO: Fact sheet, tuberculosis; 2012. Available at: http://www.who.int/
mediacentre/factsheets/fs104/en/index.html.
48. Barton ES, White DW, Cathelyn JS, Brett-McClellan KA, Engle M, Diamond
MS, Miller VL, Virgin HW 4th: Herpesvirus latency confers symbiotic pro-
tection from bacterial infection. Nature 2007, 447:326–329.
doi:10.1186/1471-2334-13-573
Cite this article as: Savolainen et al.: Cytotoxic response persists in
subjects treated for tuberculosis decades ago. BMC Infectious Diseases
2013 13:573.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
